ERBB2 and gastric cancer: In this study, ERBB2/HER2 alteration rates were similar to the gastric cancer cohort (9.5% genomic alteration rate), however 69% of these alterations were amplifications in gastric cancer, as opposed to just 23% in SBAs [1].